|
|
难治性甲状腺功能减退合并甲状腺相关眼病及甲状腺肢端肥大病因分析及研究进展
|
Abstract:
目的：探讨难治性甲状腺功能减退的病因、并发症、治疗和预后。方法：对难治性甲状腺功能减退合并甲状腺相关眼病及甲状腺肢端肥大患者进行病因分析并总结研究进展。结果：不规律应用左甲状腺素治疗甲状腺功能减退后出现难治性甲状腺功能减退，并发甲状腺相关眼病及甲状腺肢端肥大，调节左甲状腺素用量及糖皮质激素冲击治疗可缓解其症状。结论：难治性甲状腺功能减退合并甲状腺相关眼病、甲状腺肢端肥大的病例是极少见的，原因与患者依从性差、吸烟和甲状腺自身抗体阳性等密切相关。此外，可能还有其他没有观察到的原因。当面对这类病人时，应该关注其风险因素及调整治疗方案，必要时启动糖皮质激素冲击治疗。
Objective: To explore the etiology, complications, treatment, and prognosis of refractory hypothyroidism. Method: Analyze the etiology of refractory hypothyroidism combined with thyroid related ophthalmopathy and acromegaly, summarize the research progress on it. Result: Irregular use of levothyroxine in the treatment of hypothyroidism resulted in refractory hypothyroidism, accompanied by thyroid related eye disease and thyroid acromegaly. Adjusting the dosage of levothyroxine and glucocorticoid shock therapy can alleviate its symptoms. Conclusion: Cases of refractory hypothyroidism combined with thyroid related ophthalmopathy and acromegaly are extremely rare, and the reasons are closely related to poor patient compliance, smoking, and positive thyroid autoantibodies. In addition, there may be other reasons that were not observed. When facing such patients, attention should be paid to their risk factors and treatment plans should be adjusted. If necessary, glucocorticoid shock therapy should be initiated.
| [1] | Centanni, M., Benvenga, S. and Sachmechi, I. (2017) Diagnosis and Management of Treatment-Refractory Hypothyroidism: An Expert Consensus Report. Journal of Endocrinological Investigation, 40, 1289-1301. https://doi.org/10.1007/s40618-017-0706-y |
| [2] | Wyse, E.P., McConahey, W.M., Woolner, L.B., et al. (1968) Ophthalmopathy without Hyperthyroidism in Patients with Histologic Hashimoto’s Thyroiditis. The Journal of Clinical Endocrinology & Metabolism, 28, 1623-1629. https://doi.org/10.1210/jcem-28-11-1623 |
| [3] | Kashkouli, M.B., Pakdel, F., Kiavash, V., et al. (2011) Hyperthyroid vs Hypothyroid Eye Disease: The Same Severity and Activity. Eye, 25, 1442-1446. https://doi.org/10.1038/eye.2011.186 |
| [4] | Bartalena, L., Baldeschi, L., Boboridis, K., et al. (2016) The 2016 European Thyroid Association/European Group on Graves’ Orbitopathy Guidelines for the Management of Graves’ Orbitopathy. European Thyroid Journal, 5, 9-26. https://doi.org/10.1159/000443828 |
| [5] | Bahn, R.S., Burch, H.B., Cooper, D.S., et al. (2011) Hyperthyroidism and Other Causes of Thyrotoxicosis: Management Guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Endocrine Practice, 17, 456-520. https://doi.org/10.4158/EP.17.3.456 |
| [6] | Mourits, M.P., Koornneef, L., Wiersinga, W.M., et al. (1989) Clinical Criteria for the Assessment of Disease Activity in Graves’ Ophthalmopathy: A Novel Approach. British Journal of Ophthalmology, 73, 639-644. https://doi.org/10.1136/bjo.73.8.639 |
| [7] | Ernst, F.R., Barr, P., Elmor, R., et al. (2017) The Economic Impact of Levothyroxine Dose Adjustments: The CONTROL HE Study. Clinical Drug Investigation, 37, 71-83. https://doi.org/10.1007/s40261-016-0462-3 |
| [8] | Wiersinga, W.M. (2019) Graves’ Disease: Can It Be Cured? Endocrinology and Metabolism, 34, 29-38. https://doi.org/10.3803/EnM.2019.34.1.29 |
| [9] | Virili, C., Antonelli, A., Santaguida, M.G., et al. (2019) Gastrointestinal Malabsorption of Thyroxine. Endocrine Reviews, 40, 118-136. https://doi.org/10.1210/er.2018-00168 |
| [10] | Wiesner, A., Gajewska, D. and Pasko, P. (2021) Levothyroxine Interactions with Food and Dietary Supplements—A Systematic Review. Pharmaceuticals, 14, Article 206. https://doi.org/10.3390/ph14030206 |
| [11] | Huang, L.L., Deng, J.H., Xie, J.X., et al. (2021) Integrin-Linked Kinase (ILK) Regulates Urinary Stem Cells Differentiation into Smooth Muscle via NF-κB Signal Pathway. Stem Cells International, 2021, Article ID: 6633111. https://doi.org/10.1155/2021/6633111 |
| [12] | 中华医学会内分泌学分会. 成人甲状腺功能减退症诊治指南[J]. 中华内分泌代谢杂志, 2017, 33(2), 167-180. |
| [13] | Flynn, R.W., Bonellie, S.R., Jung, R.T., et al. (2010) Serum Thyroid-Stimulating Hormone Concentration and Morbidity From Cardiovascular Disease and Fractures in Patients on Long-Term Thyroxine Therapy. The Journal of Clinical Endocrinology & Metabolism, 95, 186-193. https://doi.org/10.1210/jc.2009-1625 |
| [14] | Virili, C., Trimboli, P., Romanelli, F., et al. (2016) Liquid and Softgel Levothyroxine Use in Clinical Practice: State of the Art. Endocrine, 54, 3-14. https://doi.org/10.1007/s12020-016-1035-1 |
| [15] | Smith, T.J. and Hegedus, L. (2016) Graves’ Disease. The New England Journal of Medicine, 375, 1552-1565. https://doi.org/10.1056/NEJMra1510030 |
| [16] | Kahaly, G.J., Bartalena, L., Hegedus, L., et al. (2018) 2018 European Thyroid Association Guideline for the Management of Graves’ Hyperthyroidism. European Thyroid Journal, 7, 167-186. https://doi.org/10.1159/000490384 |
| [17] | Fox, T.J. and Anastasopoulou, C. (2021) Graves Orbitopathy. Stat Pearls, Treasure Island. |
| [18] | Valyasevi, R.W., Erickson, D.Z., Harteneck, D.A., et al. (1999) Differentiation of Human Orbital Preadipocyte Fibroblasts Induces Expression of Functional Thyrotropin Receptor. The Journal of Clinical Endocrinology and Metabolism, 84, 2557-2562. https://doi.org/10.1210/jc.84.7.2557 |
| [19] | Barrio, J., Sabater, A.L., Bonet-Farriol, E., et al. (2015) Graves’ Ophthalmopathy: VISA versus EUGOGO Classification, Assessment, and Management. Journal of Ophthalmology, 2015, Article ID: 249125. https://doi.org/10.1155/2015/249125 |
| [20] | Khong, J.J., Finch, S., De Silva, C., et al. (2016) Risk Factors for Graves’ Orbitopathy: The Australian Thyroid-Associated Orbitopathy Research (ATOR) Study. The Journal of Clinical Endocrinology & Metabolism, 101, 2711-2720. https://doi.org/10.1210/jc.2015-4294 |
| [21] | Drui, D., Du Pasquier Fediaevski, L., Vignal Clermont, C., et al. (2018) Graves’ Orbitopathy: Diagnosis and Treatment. Annales d’Endocrinologie, 79, 656-664. https://doi.org/10.1016/j.ando.2018.08.005 |
| [22] | 闫春芳, 张朝霞, 罗燕, 等. ABO血型与甲状腺相关眼病的相关性研究[J]. 中华眼外伤职业眼病杂志, 2023, 45(6): 440-444. |
| [23] | 中国医学会眼科学分会眼整形眼眶病学组, 中华医学会内分泌学分会甲状腺学组. 中国甲状腺相关眼病诊断和治疗指南(2022)年[J]. 中华眼科杂志, 2022, 58(9): 646-668. |
| [24] | Marcocci, C., Kahaly, G.J., Krassas, G.E., et al. (2011) Selenium and the Course of Mild Graves’ Orbitopathy. The New England Journal of Medicine, 364, 1920-1931. https://doi.org/10.1056/NEJMoa1012985 |
| [25] | Smith, T.J., Kahaly, G.J., Ezra, D.G., et al. (2017) Teprotumumab for Thyroid-Associated Ophthalmopathy. The New England Journal of Medicine, 376, 1748-1761. https://doi.org/10.1056/NEJMoa1614949 |
| [26] | Bartalena, L. and Fatourechi, V. (2014) Extrathyroidal Manifestations of Graves’ Disease: A 2014 Update. Journal of Endocrinological Investigation, 37, 691-700. https://doi.org/10.1007/s40618-014-0097-2 |
| [27] | Fatourechi, V., Ahmed, D.D. and Schwartz, K.M. (2002) Thyroid Acropachy: Report of 40 Patients Treated at a Single Institution in a 26-Year Period. The Journal of Clinical Endocrinology & Metabolism, 87, 5435-5441. https://doi.org/10.1210/jc.2002-020746 |
| [28] | Schwartz, K.M., Fatourechi, V., Ahmed, D.D., et al. (2002) Dermopathy of Graves’ Disease (Pretibial Myxedema): Long-Term Outcome. The Journal of Clinical Endocrinology & Metabolism, 87,438-446. https://doi.org/10.1210/jcem.87.2.8220 |
| [29] | Takasu, N., Higa, H. and Kinjou, Y. (2010) Treatment of Pretibial Myxedema (PTM) with Topical Steroid Ointment Application with Sealing Cover (Steroid Occlusive Dressing Technique: Steroid ODT) in Graves’ Patients. Internal Medicine, 49, 665-669. https://doi.org/10.2169/internalmedicine.49.2617 |
| [30] | Susser, W.S., Heermans, A.G., Chapman, M.S., et al. (2002) Elephantiasic Pretibial Myxedema: A Novel Treatment for an Uncommon Disorder. Journal of the American Academy of Dermatology, 46,723-726. https://doi.org/10.1067/mjd.2002.119655 |
| [31] | Vannucchi, G., Campi, I., Covelli, D., et al. (2013) Treatment of Pretibial Myxedema with Dexamethazone Injected Subcutaneously by Mesotherapy Needles. Thyroid, 23, 626-632. https://doi.org/10.1089/thy.2012.0429 |
